Agilent Technologies, Inc. (NYSE:A) CEO Sells $283,910.00 in Stock

Agilent Technologies, Inc. (NYSE:A) CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Padraig Mcdonnell also recently made the following trade(s):

• On Friday, July 26th, Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock. The shares were sold at an average price of $140.00, for a total transaction of $274,120.00.
• On Monday, June 3rd, Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00.

Agilent Technologies Stock Up 0.8 %

Agilent Technologies stock traded up $1.18 during midday trading on Friday, hitting $141.40. 464,020 shares of the company’s stock were exchanged, compared to its average volume of 1,750,320. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. Agilent Technologies, Inc. has a 12 month low of $96.80 and a 12 month high of $155.35. The firm has a 50-day moving average of $133.95 and a two-hundred day moving average of $138.49. The company has a market cap of $41.26 billion, a PE ratio of 33.20, a P/E/G ratio of 4.86 and a beta of 1.05.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the prior year, the business earned $1.43 EPS. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. As a group, analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Crewe Advisors LLC boosted its holdings in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies in the 4th quarter valued at about $26,000. VisionPoint Advisory Group LLC bought a new stake in shares of Agilent Technologies in the 4th quarter valued at about $29,000. Ridgewood Investments LLC bought a new stake in shares of Agilent Technologies in the 2nd quarter valued at about $29,000. Finally, Rise Advisors LLC boosted its holdings in shares of Agilent Technologies by 527.8% in the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after buying an additional 190 shares in the last quarter. 87.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on A. TD Cowen upped their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus reduced their target price on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a research note on Thursday, May 30th. Bank of America increased their target price on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. reduced their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a research note on Thursday, May 30th. Finally, Wolfe Research downgraded shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $140.20.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.